A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Status:
NOT_YET_RECRUITING
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label extension for an additional 24 weeks.